Ecopetrol SA vs Sanofi SA — how do they compare? Ecopetrol SA trades at $16 (market cap $30.44B), while Sanofi SA trades at $44.11 (market cap $103.94B). The key difference: Sanofi SA is far larger — about 3.4× Ecopetrol SA's market cap, and Sanofi SA pays the higher dividend (5.54%). Which is the better fit depends on your goals.
| EC | SNY | |
|---|---|---|
Market Cap | $30.44B | $103.94B |
Sector | Energy | Health |
52-Week High | $16.58 | $52.34 |
52-Week Low | $8.29 | $41.33 |
Enterprise Value | $58.23B | $120.43B |
Dividend Yield | 4.06% | 5.54% |
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.16, up 1.76% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company maintains solid profitability with an 8.76% net margin and 13.01% ROE, though revenue has declined from $159.6T in 2022 to $119.7T in 2025. Recent developments include a finalized labor agreement with the USO union and S&P affirming its BB- credit rating with a stable outlook on June 17, 2026.
The stock presents a mixed outlook: valuation appears reasonable with a P/E of 11.39, but earnings misses and declining revenue pose risks. Analyst consensus is cautious with a $14.63 price target below current levels. Key opportunities include stable cash flow and dividend payments, while risks involve oil price volatility and execution challenges in a competitive energy sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →